Financial StabilityCATX reported a preliminary estimated unaudited cash position of ~$227.8M, which is expected to fund operations into late 2026, indicating strong financial stability.
Growth OpportunitiesCATX is continuing to evaluate potential expansion into other SSTR2 tumor types, suggesting growth opportunities.
Safety ProfileVMT-α-NET's safety profile to date appears better than key competitor program ALPHAMEDIX.